Shanghai Haohai Biological Technology Co (FRA:5HB) Marketable Securities: €10.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5HB Shanghai Haohai Biological Technology Co Ltd FRA:5HB
66 GF Score
Price €1.76
GF Value €2.65
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Shanghai Haohai Biological Technology Co Marketable Securities?

Shanghai Haohai Biological Technology Co FRA:5HB -0.56% 66 Marketable Securities is €10.0 Mil as of Mar. 2026. GuruFocus rates FRA:5HB with a GF Score™ of 66/100 and a GF Value™ of €2.65 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Shanghai Haohai Biological Technology Co's Marketable Securities for the quarter that ended in Mar. 2026 was €10.0 Mil.

Shanghai Haohai Biological Technology Co's annual Marketable Securities increased from Dec. 2023 (€1.4 Mil) to Dec. 2024 (€11.5 Mil) but then declined from Dec. 2024 (€11.5 Mil) to Dec. 2025 (€9.2 Mil).

Shanghai Haohai Biological Technology Co  (FRA:5HB) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Shanghai Haohai Biological Technology Co Marketable Securities Related Terms

Shanghai Haohai Biological Technology Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for Shanghai Haohai Biological Technology Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Haohai Biological Technology Co Marketable Securities Chart

Shanghai Haohai Biological Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 0.00 1.42 11.52 9.23

Shanghai Haohai Biological Technology Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.52 12.51 12.82 9.23 10.01
FRA:5HB
66GF Score
Shanghai Haohai Biological Technology Co Ltd FRA:5HB
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Haohai Biological Technology Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €10.0 Mil mean?
Shanghai Haohai Biological Technology Co (FRA:5HB) has a Marketable Securities of €10.0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Shanghai Haohai Biological Technology Co and its competitors.
Is Shanghai Haohai Biological Technology Co's Marketable Securities too high?
Shanghai Haohai Biological Technology Co's current Marketable Securities is €10.0 Mil. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's Marketable Securities compare to VRTX and REGN?
Shanghai Haohai Biological Technology Co's Marketable Securities of €10.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Shanghai Haohai Biological Technology Co and its competitors. Shanghai Haohai Biological Technology Co's current Marketable Securities is €10.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co (FRA:5HB) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.65, compared to a current price of €1.76 — trading 33.6% below its estimated fair value. The current Marketable Securities is €10.0 Mil. Shanghai Haohai Biological Technology Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (FRA:5HB), the current Marketable Securities is €10.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Haohai Biological Technology Co (FRA:5HB) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued. The current stock price of €1.76 is trading 33.6% below its estimated GF Value™ of €2.65. GuruFocus considers Shanghai Haohai Biological Technology Co to be Significantly Undervalued.

Key valuation signals for FRA:5HB:

  • Marketable Securities: €10.0 Mil
  • GF Value™: €2.65 vs. price of €1.76 (33.6% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the FRA:5HB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Haohai Biological Technology Co Business Description

Other Exchanges 06826:Hong Kong688366:China
Address No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
66GF Score

Get the complete analysis for FRA:5HB

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.76
Price
€2.65
GF Value